Literature DB >> 12599022

Botulinum toxin type A may improve bladder function in a rat chemical cystitis model.

Selahittin Cayan1, Banu Coşkun, Murat Bozlu, Deniz Acar, Erdem Akbay, Ercüment Ulusoy.   

Abstract

The purpose of this study was to investigate the effect of botulinum toxin type A on bladder function and histology in a rat chemical cystitis model. The study included 41 female Sprague-Dawley rats with chemical cystitis induced by intravesical instillation of hydrochloric acid. The acid instillation was repeated monthly to maintain chronic inflammation. The treatment group (n=21) received 2-3 units of botulinum toxin type A injected into the bladder detrusor at the 3, 6, 9 and 12 o'clock positions, and the control group (n=20) underwent saline injection into the bladder detrusor at the same positions. Urodynamic studies were performed in all rats before the treatment and at death. The rats were killed at 1 week, 2 weeks, 1 month and 2 months after treatment. The bladders were removed and examined histologically for mast cells and inflammatory changes. The cystometric findings showed that, at the beginning and end of the experiment, the increases in the maximum bladder capacity and compliance were significantly higher in the treatment group than in the control group (P=0.000 and P=0.025, respectively). The histological studies revealed similar mast cell counts and leukocyte infiltration for the treatment and control groups. In conclusion, in this rat chemical cystitis model, botulinum toxin type A injected into the bladder detrusor led to a functional improvement. Thus, botulinum toxin type A injection may be an alternative, minimally invasive choice to other surgical treatment options in the treatment of a chronic inflammatory condition to improve deteriorated bladder function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12599022     DOI: 10.1007/s00240-002-0291-0

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  26 in total

1.  Treatment of neurogenic incontinence with botulinum toxin A.

Authors:  B Schurch; D M Schmid; M Stöhrer
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 2.  Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option.

Authors:  J Kirschner; S Berweck; V Mall; R Korinthenberg; F Heinen
Journal:  J Neurol       Date:  2001-04       Impact factor: 4.849

3.  Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987.

Authors:  J Y Gillenwater; A J Wein
Journal:  J Urol       Date:  1988-07       Impact factor: 7.450

Review 4.  The etiology of interstitial cystitis.

Authors:  T L Ratliff; C G Klutke; E M McDougall
Journal:  Urol Clin North Am       Date:  1994-02       Impact factor: 2.241

Review 5.  Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy.

Authors:  U Schwantes; P Topfmeier
Journal:  Int J Clin Pharmacol Ther       Date:  1999-05       Impact factor: 1.366

6.  Interstitial cystitis: bladder training with intravesical oxybutynin.

Authors:  G A Barbalias; E N Liatsikos; A Athanasopoulos; G Nikiforidis
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

7.  Urinary neutrophil chemotactic factors in interstitial cystitis patients and a rabbit model of bladder inflammation.

Authors:  S A Elgebaly; M E Allam; M P Walzak; D Oselinsky; C Gillies; H Yamase
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

8.  Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.

Authors:  J Pannek; H J Sommerfeld; U Bötel; T Senge
Journal:  Urology       Date:  2000-03       Impact factor: 2.649

Review 9.  Intravesical treatment of overactive bladder.

Authors:  C J Fowler
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

Review 10.  The role of the mast cell in interstitial cystitis.

Authors:  G R Sant; T C Theoharides
Journal:  Urol Clin North Am       Date:  1994-02       Impact factor: 2.241

View more
  7 in total

1.  Urodynamic findings in an awake chemical cystitis rat model observed by simultaneous registrations of intravesical and intraabdominal pressures.

Authors:  Long-Hu Jin; Hwa-Yeon Shin; Yong-Hyun Kwon; Chang-Shin Park; Sang-Min Yoon; Tack Lee
Journal:  Int Neurourol J       Date:  2010-04-30       Impact factor: 2.835

Review 2.  Models of inflammation of the lower urinary tract.

Authors:  Dale E Bjorling; Zun-Yi Wang; Wade Bushman
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

3.  Transurethral Instillation Procedure in Adult Male Mouse.

Authors:  Sanghee Lee; Alonso Carrasco; Randall B Meacham; Anna P Malykhina
Journal:  J Vis Exp       Date:  2017-11-02       Impact factor: 1.355

Review 4.  Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2015-06-18       Impact factor: 4.546

Review 5.  Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence.

Authors:  Chin-Li Chen; En Meng
Journal:  Toxins (Basel)       Date:  2020-02-10       Impact factor: 4.546

6.  Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.

Authors:  Xin Su; Angela Nickles; Dwight E Nelson
Journal:  BMC Urol       Date:  2015-06-09       Impact factor: 2.264

7.  Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children.

Authors:  Mazen Zeino; Tanja Becker; Mark Koen; Christoph Berger; Marcus Riccabona
Journal:  Cent European J Urol       Date:  2012-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.